Trine Strandgaard

Trine Strandgaard

Auto-generated profile, based on publicly available information

Trine Strandgaard

Department of Molecular Medicine, Aarhus University Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ECEmil Christensen
Emil Christensen
INIver Nordentoft
Iver Nordentoft
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
SESara K. Elbæk
Sara K. Elbæk
SLSia V. Lindskrog
Sia V. Lindskrog
LDLars Dyrskjøt
Lars Dyrskjøt
Purpose: To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer. Experimental Design: Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC. Results: We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003). Conclusions: Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.

23 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
TSTrine Strandgaard
Trine Strandgaard
SLSia Viborg Lindskrog
Sia Viborg Lindskrog
INIver Nordentoft
Iver Nordentoft
ECEmil Christensen
Emil Christensen
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
LDLars Dyrskjøt
Lars Dyrskjøt
Background: The functional status of immune cells within the tumor microenvironment and tumor characteristics may explain Bacillus Calmette-Guérin (BCG)-failure in high-risk non-muscle invasive bladder cancer (NMIBC). Objective: To characterize molecular correlates of BCG-failure using a multiomics approach. Design, Setting, and Participants: BCG-treated NMIBC patients (n=156) were included. Metachronous tumors were analyzed using RNA-sequencing (n=170) and whole exome sequencing (n=198). Urine samples were analyzed for immune-oncology related proteins (n=190), and tumor-derived DNA (tdDNA; n=192). Outcome Measurement and Statistical Analysis: Primary endpoint was BCG-failure. Cox regression, Wilcoxon Rank Sum test, t-test or Fisher’s exact test were used. Results and Limitations: BCG caused activation of the immune system regardless of clinical response; however, immune-inhibitory proteins were observed in the urine of BCG-unresponsive patients post-treatment (CD70, PD1, CD5). BCG-failure was associated with post-BCG T-cell exhaustion ( p =0.0021). Pre-BCG tumors from patients with post-BCG T-cell exhaustion were characterized by high expression of cell division and immune-related genes. A high post-BCG exhaustion prediction score in pre-BCG tumors was associated with worse post-BCG high-grade recurrence free survival (HGRFS), reflecting BCG-failure ( p =0.0084). Pre-BCG tumors of class 2a and 2b were likewise associated with worse post-BCG HGRFS( p =0.0023). Post-BCG exhaustion was observed in patients with high pre-BCG neoantigen load ( p =0.023) and mutations in MUC4 ( p =0.0007). Finally, absence of post-BCG tdDNA clearance identified patients at high risk of recurrence ( p =0.028). The retrospective design, lack of maintenance BCG, and partial overlap in analyses are limitations to the study. Conclusions: BCG failure may be caused by T-cell exhaustion. Tumor subtype and Pre-BCG tumor characteristics may identify patients at high risk of BCG-failure prior to treatment. Urinary measurements have the potential to be used as a real-time assessment of treatment response. Patient Summary: A dysfunctional immune response to BCG therapy may explain lack of response to the treatment.

27 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSia V. Lindskrog
Sia V. Lindskrog
SSSofie S. Schmøkel
Sofie S. Schmøkel
INIver Nordentoft
Iver Nordentoft
PLPhilippe Lamy
Philippe Lamy
MKMichael Knudsen
Michael Knudsen
LDLars Dyrskjøt
Lars Dyrskjøt
Current transcriptomic classification systems for bladder cancer do not consider the level of intra-tumor subtype heterogeneity. Here we present an investigation of the extent and possible clinical impact of intra-tumor heterogeneity across early and more advanced disease stages of bladder cancer. We performed single nucleus RNA-sequencing of 48 bladder tumors and four of these tumors were additionally analyzed using spatial transcriptomics. Total bulk RNA-sequencing and spatial proteomics data were available from the same tumors for comparison, along with detailed clinical follow-up of the patients. We demonstrate that tumors display varying levels of intra-tumor subtype heterogeneity and show that a higher class 2a weight estimated from bulk RNA-sequencing data is associated with worse outcome in patients with molecular high-risk class 2a tumors. Our results indicate that discrete subtype assignments from bulk RNA-sequencing data may lack biological granularity and continuous class scores could improve clinical risk stratification of patients. Highlights Single nucleus RNA-sequencing of tumors from 48 bladder cancer patients. Tumors display varying levels of intra-tumor subtype heterogeneity at single nucleus and bulk tumor level. The level of subtype heterogeneity could be estimated from both single nucleus and bulk RNA-sequencing data with a high concordance between the two. High class 2a weight estimated from bulk RNA-sequencing data is associated with worse outcome in patients with molecular high-risk class 2a tumors.

21 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TSTrine Strandgaard
Trine Strandgaard
INIver Nordentoft
Iver Nordentoft
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
LSLiina Salminen
Liina Salminen
FPFrederik Prip
Frederik Prip
LDLars Dyrskjøt
Lars Dyrskjøt
Bladder field cancerization may be associated with disease outcome in patients with bladder cancer. To investigate this, we analyzed biopsies from bladder urothelium and urine samples by genomics and proteomics analyses. Samples were procured from multiple timepoints from 134 patients with early stage bladder cancer and detailed long term follow-up. We measured the field cancerization in normal-appearing bladder biopsies and found that high levels were associated with high tumor mutational burden, high neoantigen load, and high tumor-associated CD8 T-cell exhaustion. Non-synonymous mutations in known bladder cancer driver genes such as KDM6A and TP53 were identified as early disease drivers in normal urothelium. High field cancerization was associated with worse outcome but not with response to BCG. The level of urinary tumor DNA (utDNA) reflected the bladder tumor burden and originated from both tumors and field cancerization. High utDNA levels after BCG were associated with worse clinical outcomes for the patients. Our results indicate that the level of field cancerization may affect clinical outcome, tumor development and immune responses. utDNA measurements have significant prognostic value and reflect the disease status of the bladder.

25 November 2025
Verified
Other
Open access
ECEmil Christensen
Emil Christensen
INIver Nordentoft
Iver Nordentoft
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
SESara K. Elbæk
Sara K. Elbæk
SLSia V. Lindskrog
Sia V. Lindskrog
LDLars Dyrskjøt
Lars Dyrskjøt
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.

1 April 2023
Verified
Other
Open access
ECEmil Christensen
Emil Christensen
INIver Nordentoft
Iver Nordentoft
KBKarin Birkenkamp-Demtröder
Karin Birkenkamp-Demtröder
SESara K. Elbæk
Sara K. Elbæk
SLSia V. Lindskrog
Sia V. Lindskrog
LDLars Dyrskjøt
Lars Dyrskjøt
Purpose:To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer.Experimental Design:Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC.Results:We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003).Conclusions:Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.